
    
      This study is an open-label extension study which follows on from the 6-week double-blind
      main study C87037 (NCT00291668). All 'Week' numbers quoted are relative to the start of the
      double-blind main study. The first visit in this extension study is at Week 8, and the final
      efficacy assessment in this extension study, 26 weeks later, is at Week 34.
    
  